Developing a framework to assess off-patent medicines policies in Latin America and the Caribbean

Background: Countries in Latin America and the Caribbean (LAC) often lack a systematic approach to assessing the maturity and effectiveness of their policies for promoting off-patent (generic and biosimilar) medicines. Currently, no comprehensive, region-specific methodology exists that encompasses both generics and biosimilars. The objective of this paper is to develop a framework for assessing the performance of off-patent medicines policies that LAC countries can use to identify opportunities to improve access to these medicines in their territories. Methods: Through a scoping review of over 300 studies, this study identifies key supply- and demand-side policy interventions to promote generics and biosimilars, along with corresponding outcome indicators. This informs a logic-model-based framework, where supply-side policies are organized according to the pharmaceutical value chain, and demand-side policies are based on the target population. Results: The framework maps key policy actions, such as regulation, pricing, and substitution, to expected outcomes, such as affordability, uptake, and trust. The review highlights major regional gaps, including insufficient biosimilar policies, limited empirical evaluations, and the unique duality between public and private healthcare sectors in LAC. The existing literature gives greater attention to demand-side policies as potential factors driving higher market participation in generic and biosimilar medicines. Within this component, the emphasis is on factors aimed at education and awareness initiatives for users (41.6%). Supply-side policies are discussed less frequently, with price regulation (28.9%) most cited. By contrast, limited attention is given to other key factors such as horizon scanning, and mark-up regulation. Conclusion: The proposed framework serves as a diagnostic, analytical, and benchmarking instrument for policymakers and academia. It facilitates structured assessment, supports policy design, and fosters regional learning. Piloting and further empirical research are recommended to refine and validate the framework using a specific tool designed for this purpose.

Authors

Institutions

Publication Details

Journal
Journal of Pharmaceutical Policy and Practice
Published
2026-04-27
DOI
https://doi.org/10.1080/20523211.2026.2651399
Primary Topic
Pharmaceutical Economics and Policy
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Developing a framework to assess off-patent medicines policies in Latin America and the Caribbean

Ana Amaris Caruso, Veronika J. Wirtz, Santiago Palacio-Ciro, Pamela Góngora et al.
Journal of Pharmaceutical Policy and Practice
Pharmaceutical Economics and Policy
article

Developing a framework to assess off-patent medicines policies in Latin America and the Caribbean

Ana Amaris Caruso, Veronika J. Wirtz, Santiago Palacio-Ciro, Pamela Góngora, Jaime Espín
article en

Abstract

Background: Countries in Latin America and the Caribbean (LAC) often lack a systematic approach to assessing the maturity and effectiveness of their policies for promoting off-patent (generic and biosimilar) medicines. Currently, no comprehensive, region-specific methodology exists that encompasses both generics and biosimilars. The objective of this paper is to develop a framework for assessing the performance of off-patent medicines policies that LAC countries can use to identify opportunities to improve access to these medicines in their territories. Methods: Through a scoping review of over 300 studies, this study identifies key supply- and demand-side policy interventions to promote generics and biosimilars, along with corresponding outcome indicators. This informs a logic-model-based framework, where supply-side policies are organized according to the pharmaceutical value chain, and demand-side policies are based on the target population. Results: The framework maps key policy actions, such as regulation, pricing, and substitution, to expected outcomes, such as affordability, uptake, and trust. The review highlights major regional gaps, including insufficient biosimilar policies, limited empirical evaluations, and the unique duality between public and private healthcare sectors in LAC. The existing literature gives greater attention to demand-side policies as potential factors driving higher market participation in generic and biosimilar medicines. Within this component, the emphasis is on factors aimed at education and awareness initiatives for users (41.6%). Supply-side policies are discussed less frequently, with price regulation (28.9%) most cited. By contrast, limited attention is given to other key factors such as horizon scanning, and mark-up regulation. Conclusion: The proposed framework serves as a diagnostic, analytical, and benchmarking instrument for policymakers and academia. It facilitates structured assessment, supports policy design, and fosters regional learning. Piloting and further empirical research are recommended to refine and validate the framework using a specific tool designed for this purpose.

Journal of Pharmaceutical Policy and PracticeVol. 19(1)
Boston University (US), Inter-American Development Bank (US), Instituto de Investigación Biosanitaria de Granada (ES), Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (ES), University of York (GB), Marymount University (US), Andalusian School of Public Health (ES)
Inter-American Development Bank
Partnerships for the goals
Openalex Percentile: Top 9%
Pharmaceutical Economics and Policy
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.